Shocking on January 24, in the presence of the CEO of the Pune-based company, Adar Poonawalla, and Prakash Kumar Singh, Union Home Minister Amit Shah unveiled the Serum Institute-made HPV vaccine “CERVAVAC.”
Each dose of Poonawalla’s “CERVAVAC” vaccination would cost between Rs 200 and Rs 400, the company predicted in September 2022.
We have provided the facts and accurate information about vaccine-related injuries (sudden or unexpected deaths) from our Expert teams and AIM teams for the past two years on Qvive Network. In every video on Qvive.in about vaccinations, the risks associated with them are discussed.
Now that you are aware of the government’s utter lack of knowledge regarding the negative effects of vaccinations, you may wonder why the mainstream media is keeping quiet. Why was there no investigation into this matter?
A deliberate attempt by the Minister to obtain HPV Vaccines
The Health Ministry intends to roll out HPV vaccine against cervical cancer in the national immunization programme for girls aged 9 to 14 years in June for which a global tender is likely to be floated in April, official sources have said. Serum Institute’s made-in-India HPV vaccine “CERVAVAC” was launched by Union Home Minister Amit Shah on January 24, in presence of the Pune-based firm’s CEO Adar Poonawalla and Prakash Kumar Singh, its Director-Government and Regulatory Affairs.
“The ministry is likely to float in April a global tender for 16.02 crore doses of HPV vaccine, which will be supplied by 2026. Apart from domestic manufacturer Serum Institute of India, global vaccine manufacturer Merck is also likely to participate in the tender,” an official source said.
In July last year, India’s drug regulator granted market authorization to Serum Institute of India’s indigenously developed HPV vaccine. It has also been cleared by government advisory panel National Technical Advisory Group on Immunisation (NTAGI) for use in the public health programme.
Prakash Kumar Singh, on the sidelines of a South Asia meet on HPV last month, had said that the price of CERVAVAC will be affordable compared to the international HPV vaccine available in India.
India, at present, is fully dependent on foreign manufacturers for HPV vaccines. Globally, three foreign firms manufacture HPV vaccines out of which two sell their doses in India.
Each dose of the vaccine available in the market costs more than Rs 4,000, sources said
In September 2022, Poonawalla had said that each dose of its “CERVAVAC” vaccine would cost Rs 200 to Rs 400.
India, which is home to about 16 percent of the world’s women, accounts for about a quarter of all cervical cancer incidences and nearly a third of global cervical cancer deaths.
On what prevented India from introducing the HPV vaccine till now, NTAGI chief Dr N K Arora had said that the vaccine supply has been a limiting factor globally.
India has taken a lead in this direction. Serum Institute of India, one of the major Indian vaccine manufacturers, with support from the Centre’s Department of Biotechnology has developed four valent HPV vaccines.
The vaccine has received regulatory approval and cleared by NTAGI for use in public health programs.
“We are given to understand that three other Indian vaccine manufacturers are also in various stages of developing the HPV vaccine,” an official had said.
Source: Businessinsider, Mint
Additional Information on HPV VAccine and its Side Effects
What is human papillomavirus (HPV) 9-valent vaccine?
Human papillomavirus (HPV) is a sexually transmitted disease that can cause genital warts. HPV can also cause anal cancer or various cancers of the cervix, vagina, vulva, oropharynx (the middle part of the throat), or head and neck.
You should not receive a booster vaccine if you have had a life-threatening allergic reaction after the first shot.
You may feel faint during the first 15 minutes after receiving this vaccine. Some people have had seizure-like reactions after receiving this vaccine.
HPV 9-valent vaccine side effects
Get emergency medical help if you have signs of an allergic reaction:
hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Common side effects of the human papillomavirus (HPV) vaccine, 9-valent may include:
- pain, swelling, redness, itching, bruising, bleeding, and a lump where the shot was given;
- nausea, diarrhea, stomach pain;
- sore throat;
- dizziness; or
some people may have a more severe allergic reaction, called an anaphylactic reaction, immediately after HPV vaccination.
For Healthcare Professionals
Applies to human papillomavirus vaccine: intramuscular suspension.
The most common adverse events were injection site reactions, fatigue, headache, and myalgia.
Very common (10% or more): Injection site pain (91.9%), injection site swelling (49%), injection site erythema (48.4%)
Common (1% to 10%): Injection site pruritus, injection site hematoma, injection site induration, injection site hemorrhage, injection site warmth, injection site mass, injection site reaction
Postmarketing reports: Injection site cellulitis
Deaths occurred during clinical trials which were generally assessed as not vaccine-related:
car accidents, suicides, acute lymphocytic leukemia, hypovolemic septic shock, airplane crash, cerebral hemorrhage, gunshot wound, stomach adenocarcinoma, pulmonary embolus/deep vein thrombosis, sepsis, pancreatic cancer, arrhythmia, pulmonary tuberculosis, hyperthyroidism, post-operative pulmonary embolism and acute renal failure, traumatic brain injury/cardiac arrest, systemic lupus erythematosus, cerebrovascular accident, breast cancer, nasopharyngeal cancer, autoimmune disease, infectious disease, homicide, and 1 unexplained sudden death 678 days following the last vaccine dose.
Very common (10% or more): Fatigue (54.6%), headache (53.4%), pyrexia (13%), fever of 99.5F or higher (12.9%)
Common (1% to 10%): Chlamydia infection, malaise
Uncommon (0.1% to 1%): Death
Postmarketing reports: Asthenia, chills
Very common (10% or more): Myalgia (48.8%), arthralgia (20.7%)
Common (1% to 10%): Back pain
Postmarketing reports: Pain in extremity
Common (1% to 10%): Nausea, diarrhea, vomiting, abdominal pain upper, toothache
Rare (less than 0.1%): Appendicitis, gastroenteritis
Postmarketing reports: Pancreatitis
Common (1% to 10%): Nasopharyngitis, oropharyngeal pain, influenza, cough, nasal congestion, upper respiratory tract infection, pharyngitis
Rare (0.01% to 0.1%): Pneumonia, pulmonary embolism, asthma
Very rare (less than 0.01%): Bronchospasm
Frequency not reported: Asthmatic crisis
Postmarketing reports: Pulmonary embolus
Common (1% to 10%): Dizziness, migraine
Postmarketing reports: Acute disseminated encephalomyelitis, Guillain-Barre syndrome, motor neuron disease, paralysis, seizures, syncope (including syncope associated with tonic-clonic movements and other seizure-like activity) sometimes resulting in falling with injury, transverse myelitis
New medical conditions potentially indicative of systemic autoimmune disorders included: arthralgia/arthritis/arthropathy, autoimmune thyroiditis, celiac disease, diabetes mellitus insulin-dependent, erythema nodosum, hyperthyroidism, hypothyroidism, inflammatory bowel disease, multiple sclerosis, nephritis, optic neuritis, pigmentation disorder, psoriasis, Raynaud’s phenomenon, rheumatoid arthritis, scleroderma/morphea, Stevens-Johnson syndrome, systemic lupus erythematosus, uveitis, alopecia areata, ankylosing spondylitis, autoimmune thrombocytopenia, myocarditis, proteinuria, skin depigmentation, dermatomyositis, vasculitis, and vitiligo.
Common (1% to 10%): New medical conditions potentially indicative of systemic autoimmune disorders
Postmarketing reports: Autoimmune diseases
Common (1% to 10%): Injection site hypersensitivity
Frequency not reported: Allergy to vaccine
Postmarketing reports: Hypersensitivity reactions (including anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria)
Uncommon (0.1% to 1%): Lymphadenopathy
Postmarketing reports: Autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura
Common (1% to 10%): Insomnia
Common (1% to 10%): Dysmenorrhea, vaginal infection, urinary tract infection
Rare (less than 0.1%): Pelvic inflammatory disease, pyelonephritis
Common (1% to 10%): Rash, urticaria, itching/pruritus
Postmarketing reports: Cellulitis, angioedema, erythema multiforme
Postmarketing reports: Deep vein thrombosis
Source: drugs, nhs
📍Marco Cavaleri, the head of the office of biological health threats and vaccines strategy, expressed concern that people are getting blood clots, but Adar poonawala ignored that report and continued to say that vaccinations are safe.